These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 24632568)

  • 21. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
    Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
    Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
    Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
    Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
    Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
    Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
    Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
    Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
    Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
    Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
    Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
    Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
    J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
    Asleh K; Brauer HA; Sullivan A; Lauttia S; Lindman H; Nielsen TO; Joensuu H; Thompson EA; Chumsri S
    Clin Cancer Res; 2020 Jun; 26(11):2603-2614. PubMed ID: 32005747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
    Wong CK; Gromisch C; Ozturk S; Papageorgis P; Abdolmaleky HM; Reinhard BM; Thiagalingam A; Thiagalingam S
    Cancer Biol Ther; 2019; 20(8):1113-1120. PubMed ID: 30922194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation.
    Dong G; Liang X; Wang D; Gao H; Wang L; Wang L; Liu J; Du Z
    Med Oncol; 2014 Jul; 31(7):57. PubMed ID: 24930006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    Kalecky K; Modisette R; Pena S; Cho YR; Taube J
    BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy.
    Abdul Aziz AA; Md Salleh MS; Yahya MM; Zakaria AD; Ankathil R
    Asian Pac J Cancer Prev; 2022 Mar; 23(3):1053-1059. PubMed ID: 35345380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.